Elizabeth C. McCulla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elizabeth C. McCulla has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Andrii Balia
Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan
9 shared publications - Cristina Castillo
Department of Molecular & Physiology, University of Michigan, Ann Arbor, MI, USA
9 shared publications - Hannah Noelle Bell
Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan
9 shared publications - Indrani Talukder
Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan
9 shared publications - Jianping He
Department of Biological Sciences, University of Notre Dame, Notre Dame, USA
9 shared publications - Joao A. Paulo
Department of Cell Biology, Harvard Medical School, Boston, MA, USA
9 shared publications
Latest Publications
- Open Access
Rac1 and CHK1 Converge on Abi-1 to Regulate DNA Repair Dependency and Treatment Response in Human Cancers
Radiation therapy (RT) resistance remains a major clinical challenge, yet biomarkers guiding precision radiosensitization are lacking. We previously demonstrated that Rac1 promotes RT resistance in glioblastoma (GBM) by inducing Abi-1-S323 dephosphorylation and enhancing non-homologous end joining (NHEJ). Here, we identify Abi-1-S323 as a key regulator of DNA repair states and a determinant of therapeutic efficacy in human cancers. Clinically, loss of Abi-1-S323 phosphorylation was associated with poor outcomes in patients with RT-treated GBM. Bioinformatic analyses revealed that non-small cell lung cancer (NSCLC) and head and neck cancer (HNC) are among the cancers with frequent RAC1 amplification, suggesting that these tumor types may have increased Rac1-Abi-1 signaling activity. Loss of Abi-1-S323 phosphorylation also predicted poor outcomes in patients with RT-treated HNC. Consistent with these clinical observations, high Rac1 activity and low Abi-1-S323 phosphorylation were associated with enhanced DNA double-strand break repair and radioresistance in NSCLC and HNC models, whereas genetic or pharmacological inhibition of this signaling impaired DNA repair and radiosensitized tumors in vitro and in vivo . Mechanistically, we identified CHK1 as a kinase that phosphorylates Abi-1 at S323 and defines an alternative homologous recombination (HR)-dependent repair state. Tumors with high Rac1-Abi-1 signaling exhibited elevated NHEJ capacity and were selectively radiosensitized by Rac1 inhibition, whereas tumors with low Rac1-Abi-1 signaling displayed high CHK1 activity, preferentially relied on HR, and were selectively radiosensitized by CHK1 inhibition. These findings establish Abi-1-S323 as a biomarker defining therapeutically distinct DNA repair states and provide a framework for precision radiosensitization. Significance: Radiation resistance remains a major barrier to cancer treatment. We identify Abi-1-S323 phosphorylation as a biomarker of distinct DNA repair states and therapeutic vulnerabilities, providing a framework for precision radiosensitization.
Open AccessRac1 and CHK1 Converge on Abi-1 to Regulate DNA Repair Dependency and Treatment Response in Human Cancers
Radiation therapy (RT) resistance remains a major clinical challenge, yet biomarkers guiding precision radiosensitization are lacking. We previously demonstrated that Rac1 promotes RT resistance in glioblastoma (GBM) by inducing Abi-1-S323 dephosphorylation and enhancing non-homologous end joining (NHEJ). Here, we identify Abi-1-S323 as a key regulator of DNA repair states and a determinant of therapeutic efficacy in human cancers. Clinically, loss of Abi-1-S323 phosphorylation was associated with poor outcomes in patients with RT-treated GBM. Bioinformatic analyses revealed that non-small cell lung cancer (NSCLC) and head and neck cancer (HNC) are among the cancers with frequent RAC1 amplification, suggesting that these tumor types may have increased Rac1-Abi-1 signaling activity. Loss of Abi-1-S323 phosphorylation also predicted poor outcomes in patients with RT-treated HNC. Consistent with these clinical observations, high Rac1 activity and low Abi-1-S323 phosphorylation were associated with enhanced DNA double-strand break repair and radioresistance in NSCLC and HNC models, whereas genetic or pharmacological inhibition of this signaling impaired DNA repair and radiosensitized tumors in vitro and in vivo . Mechanistically, we identified CHK1 as a kinase that phosphorylates Abi-1 at S323 and defines an alternative homologous recombination (HR)-dependent repair state. Tumors with high Rac1-Abi-1 signaling exhibited elevated NHEJ capacity and were selectively radiosensitized by Rac1 inhibition, whereas tumors with low Rac1-Abi-1 signaling displayed high CHK1 activity, preferentially relied on HR, and were selectively radiosensitized by CHK1 inhibition. These findings establish Abi-1-S323 as a biomarker defining therapeutically distinct DNA repair states and provide a framework for precision radiosensitization. Significance: Radiation resistance remains a major barrier to cancer treatment. We identify Abi-1-S323 phosphorylation as a biomarker of distinct DNA repair states and therapeutic vulnerabilities, providing a framework for precision radiosensitization.
- Open Access
- 18 September 2026
- Published by Springer Nature in Research Square
Microenvironment-derived acetylated amino acids promote glioblastoma treatment resistance
Rapid repair of genotoxic therapy induced DNA damage mediates treatment resistance in glioblastoma (GBM). The role of non-malignant cell types in the tumor microenvironment in accelerating DNA repair in neoplastic cells is poorly understood. Using spatial transcriptomics, immunofluorescence, metabolomics, patient tissues and preclinical models, we show that tumor associated macrophages (TAMs) in GBM promote DNA repair and treatment resistance in neoplastic cells through the secretion of acetylated amino acids. These acetylated amino acids are consumed by GBM cells, leading to enhanced acetyl Co-A levels, histone acetylation and nucleotide synthesis. Interrupting histone acetylation via inhibition of the acetyltransferase KAT5 breaks these metabolic links and reverses the protective capacity of microenvironment-derived acetylated amino acids and TAMs. Blocking the exchange of acetylated amino acids and their downstream effects is a potential strategy for the treatment of GBM.
- 18 September 2026
- Published by Springer Nature in Research Square
Open AccessMicroenvironment-derived acetylated amino acids promote glioblastoma treatment resistance
Rapid repair of genotoxic therapy induced DNA damage mediates treatment resistance in glioblastoma (GBM). The role of non-malignant cell types in the tumor microenvironment in accelerating DNA repair in neoplastic cells is poorly understood. Using spatial transcriptomics, immunofluorescence, metabolomics, patient tissues and preclinical models, we show that tumor associated macrophages (TAMs) in GBM promote DNA repair and treatment resistance in neoplastic cells through the secretion of acetylated amino acids. These acetylated amino acids are consumed by GBM cells, leading to enhanced acetyl Co-A levels, histone acetylation and nucleotide synthesis. Interrupting histone acetylation via inhibition of the acetyltransferase KAT5 breaks these metabolic links and reverses the protective capacity of microenvironment-derived acetylated amino acids and TAMs. Blocking the exchange of acetylated amino acids and their downstream effects is a potential strategy for the treatment of GBM.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S5 shows oxidative stress markers, apoptosis, systemic toxicity, and histological outcomes following in vivo auranofin treatments in mouse models.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S5 shows oxidative stress markers, apoptosis, systemic toxicity, and histological outcomes following in vivo auranofin treatments in mouse models.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S2 validates GPX4 knockdown efficacy, details antioxidant enzyme activities under RSL3 and auranofin treatments, and includes kinetic assays for thioredoxin reductase activity in CRC cells.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S2 validates GPX4 knockdown efficacy, details antioxidant enzyme activities under RSL3 and auranofin treatments, and includes kinetic assays for thioredoxin reductase activity in CRC cells.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S7 shows the impact of AlkBH8 KD on GPX1/2 protein levels, CRC cell growth, colony formation, and tests the rescuing effects of sodium selenite under RSL3 and auranofin treatments.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S7 shows the impact of AlkBH8 KD on GPX1/2 protein levels, CRC cell growth, colony formation, and tests the rescuing effects of sodium selenite under RSL3 and auranofin treatments.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S1 shows GPX4 stability using CETSA assays and CRC cell growth responses to RSL3 treatment, with or without Liproxstatin-1 rescue.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S1 shows GPX4 stability using CETSA assays and CRC cell growth responses to RSL3 treatment, with or without Liproxstatin-1 rescue.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
This methods details synthetic procedures for biotinylated analogs, including reagents, conditions, and yields.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
This methods details synthetic procedures for biotinylated analogs, including reagents, conditions, and yields.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S6 explores the functional importance of selenoproteins in CRC via CRISPR co-essentiality analyses, qPCR validations of AlkBH8 KD, and survival analyses of tRNA-sec biosynthetic pathway genes.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S6 explores the functional importance of selenoproteins in CRC via CRISPR co-essentiality analyses, qPCR validations of AlkBH8 KD, and survival analyses of tRNA-sec biosynthetic pathway genes.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S4 provides CETSA data to illustrate the absence of direct GPX4 interaction with the compound auranofin in treated cells.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S4 provides CETSA data to illustrate the absence of direct GPX4 interaction with the compound auranofin in treated cells.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S3 shows selenoprotein expression validations upon selenium supplementation and identifies RSL3 targets through AP-MS proteomic analysis.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S3 shows selenoprotein expression validations upon selenium supplementation and identifies RSL3 targets through AP-MS proteomic analysis.